相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
Mario Luca Morieri et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes
Mario Luca Morieri et al.
CARDIOVASCULAR DIABETOLOGY (2021)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
Salim Yusuf et al.
LANCET (2020)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Gregory G. Schwartz et al.
CIRCULATION (2020)
A statement of the Committee of the Czech Society for Atherosclerosis on the 2019 ESC/EAS guidelines for the diagnosis and treatment of dyslipidemia
Michal Vrablik et al.
COR ET VASA (2020)
Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease
Fatima Rodriguez et al.
JAMA CARDIOLOGY (2019)
Current pharmacotherapeutic options for primary dyslipidemia in adults
Arrigo F. G. Cicero et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Guy De Backer et al.
ATHEROSCLEROSIS (2019)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Robert P. Giugliano et al.
CIRCULATION (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
2016 ESC/EAS Guidelines for the management of dyslipidaemias Summary of the document prepared by the Czech Society of Cardiology
Petr Jansky et al.
COR ET VASA (2017)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
Stephen J. Nicholls et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
分享论文
